Approved for use through 07/31/2006 OMB 0651-0031 tent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

	Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid. QMB control number.						
Substitute	for form 1449A/PTO			Application Number	10/520,771		
				Filing Date	December 5, 2005		
	FORMATION DIS			First Named Inventor	Mohammad Reza MEHRABI		
5	IAIEMENIBYA	(PP	LICANI	Art Unit	1614		
(Use as many sheets as necessary)				Examiner Name	Timothy P. THOMAS		
Sheet	1	of	2	Attorney Docket No.	B47357		

ILS DATENT DOCUMENTS

			U.S	PATENT D	OCUMENTS			
Examiner Initials	Cite No.1	Document No. No. – Kind Code ²	Pub	A-DD-YYYY	Name of Patentee or Applicant of Cited Doc	Pages, Passa	Columns, Lines, Where Re iges or Relevant Figures Ap	elevan
			-					
			-					
			+					
					IT DOCUMENTS			
Examiner Initials	Cite No.1	Foreign Patent Document Country Code ³ Number ⁴ Kind Co		Publication Date MM-DD-YYYY	Name of Patentee or Appl Doc	icant of Cited	Pages, Columns. Lines Where Relevant Passages or Relevant Figures Appear	T
	1 1			l	1			

	EXAMINER SIGNATURE	DATE CONSIDERED	
ı	SIGNATURE	CONSIDERED	1

EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 600. Draw line through citation if not in conformance and not considered, include copy in this form with next communication to applicant. "Applicant's unique citation designation number (options)." See Kinds Codes of communication of the part of the communication of the part of codes of the communication of the part of the region of the Emperior must precede the sensit number of the patient document. "Sind of document by the appropriate symbols are mark before the communication of the year of the region of the Emperior must precede the sensit number of the patient document." Sind of document by the appropriate symbols are mark before the communication of the comm

This collection of information is required by 37 CFR 197 and 198. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) and application. Conditionality is operanted by 58 US C 122 and 37 CFR 114 This collection is estimated to take two complete including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time, you require to complete this from andividual case (Any Comments on Trademark Office, U.S. Department of Commerce, P.O. Box 1460, Alexandra, VA.22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO Commissioner for Patents, P.O. Box 1450, Alexandra, VA.22313-1450.

Approved for use through 07/31/2006 OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Linder the Panerwork Reduction Act of 1996, no persons are required to respond to a collection of information unless it displays a valid OMB cotton tumber

Substitute for	r form 1449A/P	то		Application Number	10/520,771
				Filing Date	June 27, 2008
	ORMATION			First Named Inventor	Mohammad Reza MEHRABI
514	ATEMENT E	ST APP	LICANI	Art Unit	1614
(Use as many sheets as necessary)				Examiner Name	Timothy P. THOMAS
Sheet	2	of	2	Attorney Docket No.	B47357

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*					
		PACHER, ET AL. "Beneficial hemodynamic effects of prostaglandin E ₁ Infusion In catecholamine- dependent heart failure: Results of a prospective, randomized, controlled study"; Critical Care Medicine; July 1994; pp. 1984-1999; Vol. 22, No. 7; Williams & Wilkins; US			
		PACHER, ET AL. "Ambulatory vasodilator therapy in heart failure: systematic review of the literature and personal observational experience"; The European Journal of Heart Failure; The European Society of Cardiology; 1999; pp. 263-267; Elsevieir			
		STANEK; "Pharmacologic Bridging With Prostaglandin E1 Before Heart Transplantation – A New Chance for an Old Drug"; Journal of Clinical and Basic Cardiology; 2002; pp. 171-177; Issue 2			
		BERGER, ET AL. "Levosimendan and prostaglandin E1 for uptitration of beta-blockade in patients with refractory, advanced chronic heart failure"; The European Journal of Heart Failure; 2007; pp. 202-208; Vol. 9; Elsevier			
		HÜLSMANN, ET AL. "Hemodynamic And Neurohumoral Effects of Long-term Prostaglandin E ₁ Infusions in Outpatients With Severe Congestive Heart Fallure"; The Journal of Heart and Lung Transplantation; May 1997; pp. 556-562; Vol. 16, No. 5; International Society for Heart and Lung Transplantation			
	-				

	EXAMINER SIGNATURE	/Timothy Thomas/	CONSIDERED	10/20/2008					
į	THE PROPERTY OF THE PROPERTY O								

considered. Include copy of this form with next communication to applicant.

I Applicant unique dation designation number (optional). Applicant is to place a choick mark here if English language Translation is attached. This collection of information is equived by 3 CTRF (15 year 4) 58! The information is required to obtain or settin a benefit by the public vibro is not long for information. The confidentiality is governed by 35 U.S. C. 122 and 37 CTRF 1.14. This collection is estimated to take 2 hours to complete, including gathering, presenting, and submitting the completed application form to the UPSTP. Three will vary depending upon the individual case comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Cfficer, U.S. Pastertined Trademarks Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, W.Z. 2313-1430. D. NOT SESIN TESS OR COMPLETED KINST OT THIS ADDRESS SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.